ArticleJournal of translational medicine2026
Integrative machine learning identifies a TEAD4-driven endothelial program shaping drug sensitivity and microvascular invasion in HCC.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
aimMicrovascular invasion (MVI) drives early recurrence and poor survival in hepatocellular carcinoma (HCC). While tumor cell invasiveness has been well explored, the contribution of endothelial cells (ECs) to MVI and treatment response, including mechanisms of drug resistance, remains unclear. This study aimed to characterize endothelial programs linked to MVI and to develop a machine learning model for prognostic and therapeutic prediction.
methodsWe integrated single-cell RNA sequencing and spatial transcriptomics from HCC samples with different MVI status. Endothelial heterogeneity was analyzed using pseudotime trajectories, transcription factor networks, and cell–cell communication. Spatial mapping with cell2location and Spotlight localized endothelial subsets and defined their distribution around tumor nests and invasive fronts. A machine learning prognostic model based on Hippo–YAP pathway regulators was constructed, and drug-response patterns were assessed using CTRP and PRISM datasets. Key regulators were validated through tube formation and proliferation assays.
resultsWe identified an endothelial subset with strong Hippo–YAP activation that was enriched in MVI⁺ tumors and positioned at the peritumoral invasive front. These cells showed stem-like features and marked angiogenic potential. TEAD4 emerged as the dominant downstream transcription factor, driving APLN, ANGPT2, and VEGFA expression. TEAD4 inhibition reduced tube formation and limited tumor cell proliferation. The Hippo–YAP–based prognostic model, generated through integrative machine learning, outperformed clinical variables and existing signatures across multiple cohorts. High-risk scores correlated with immunosuppressive features and heightened sensitivity to microtubule- and cell-cycle–targeting drugs, including paclitaxel, irinotecan, and ispinesib.
conclusionThis study reveals a TEAD4-centered endothelial program that promotes angiogenesis and MVI in HCC. The machine learning–based prognostic model provides a robust tool for risk assessment and may help guide future therapeutic strategies targeting endothelial signaling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.